PHASQ PhaseBio (PNK) at $0.000001 on 28 Jan 2026: top losers insight
PHASQ stock plunged to $0.000001 on the PNK exchange during market hours on 28 Jan 2026, a collapse of -99.00% that places PhaseBio Pharmaceuticals, Inc. among today’s top losers. Trading volume was 2,500.00 shares, well below the 50-day average of 22,310.00, and the share price now sits near its year low of $0.000001. We examine why the move occurred, how company fundamentals and sector context relate, and what the immediate outlook looks like for investors in the United States and overseas.
PHASQ stock plunge and intraday drivers
The main fact is the intraday drop to $0.000001 on PNK, reflecting a -99.00% one-day change and a previous close of $0.000100. Market reporting flagged potential delisting risk and low liquidity, which likely amplified selling pressure and volatility during market hours. MarketBeat report on delisting risk provides the latest public notice that aligns with the price move and thin trading.
PHASQ stock fundamentals and financials
PhaseBio Pharmaceuticals, Inc. remains a clinical-stage biotechnology company focused on cardiovascular therapies and reversal agents. The company reports EPS -2.14 and a trailing PE metric driven by losses; key ratios include current ratio 1.75 and cash per share $1.42. These metrics show cash runway considerations but continued net losses and negative book value per share, which help explain investor caution.
PHASQ stock technicals and trading profile
Technically, PHASQ showed heavy decay: 50-day average $0.000236 and 200-day average $0.000666 point to sustained lower pricing. Average daily volume sits at 22,310.00 shares versus today’s 2,500.00, indicating very low liquidity and risk of wide spreads on execution. Low liquidity has made PHASQ a textbook top loser in small-cap biotech trading.
Meyka AI rates PHASQ with a score out of 100
Meyka AI rates PHASQ with a score out of 100: 58.98 (Grade C+) – SUGGESTION: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The C+ grade reflects cash on hand but material operational losses and delisting risk. These grades are not guaranteed and are for informational purposes only.
PHASQ stock risks, sector context and catalysts
PHASQ sits in the Biotechnology sector where clinical, regulatory and listing-status risks dominate performance. Primary risks include potential delisting, clinical program setbacks for bentracimab (PB2452), and limited liquidity. Potential catalysts would be a successful Chapter 11 reorganization update, a clear Nasdaq delisting resolution, or positive Phase III data, but none are confirmed during market hours on 28 Jan 2026.
PHASQ stock outlook and analyst-style price perspective
Analyst-style view: given current fundamentals and trading, short-term downside risk dominates while upside requires major news. Reasonable price targets in a recovery scenario start at $0.01 and extend to $0.05 if regulatory or clinical turnaround occurs, but those targets imply large upside from current levels and are highly conditional. Investors should expect extreme volatility and low liquidity on PNK in USD trading.
Final Thoughts
Key takeaways: PHASQ stock traded at $0.000001 on 28 Jan 2026 on the PNK exchange in the United States with a one-day decline of -99.00% and volume 2,500.00 which signals severe liquidity stress and delisting concern. Meyka AI’s forecast model projects $0.00 versus the current price $0.000001, implying a near-complete downside on the model’s baseline; forecasts are model-based projections and not guarantees. Meyka AI assigns PHASQ a C+ (58.98) score with a HOLD suggestion, reflecting cash metrics but heavy operational losses and listing risk. For traders focused on top losers, PHASQ is a high-risk, event-driven situation where any recovery hinges on clear regulatory or restructuring news. We recommend tight risk controls and monitoring of official company filings and delisting notices before considering exposure. Meyka AI provides this as one part of our AI-powered market analysis platform and this is not financial advice.
FAQs
What caused the PHASQ stock crash on 28 Jan 2026?
The crash tracks to delisting risk reports, extremely low liquidity and continued losses. MarketBeat flagged potential delisting, and trading fell to $0.000001 with volume 2,500.00.
What is Meyka AI’s current rating for PHASQ stock?
Meyka AI rates PHASQ 58.98 (Grade C+) with a HOLD suggestion. The grade balances cash metrics against losses and sector risk and is not investment advice.
Does Meyka AI forecast upside for PHASQ stock?
Meyka AI’s forecast model projects $0.00 versus current $0.000001, implying no modeled upside. Forecasts are projections and not guarantees; positive catalysts would be required for recovery.
Is PHASQ stock tradable and liquid on PNK?
Liquidity is very low: today’s volume 2,500.00 versus avg 22,310.00. Expect wide spreads and execution risk on PNK in USD trading hours until liquidity improves.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
